Advances in Heart Failure: A Year of Discovery – SGLT2 Inhibitor Trials and Implications for Practice
Published: 20 August 2020
-
Views:
57
-
Likes:
7
-
Views:
57
-
Likes:
7
-
19m 8s
-
15m 58s
-
11m 46s
Overview
This programme focuses on assessing recent data on SGLT2 inhibitors that show they reduce CV outcomes, HF hospitalisations and mortality in HFrEF patients irrespective of T2DM .
The expert panel also discuss how these agents should be utilised in clinical practice within GDMT, as well as considering potential application of the agents in HFpEF
Learning Objectives
- Evaluate Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors in Patients With or Without T2DM
- Interpret the New Data on the Treatment of Heart Failure With SGLT2 Inhibitors in Patients With or Without T2DM in Relationship to the Existing Data
- Understand the Implementation of the Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors in Patients With or Without T2DM for Clinical Practice
More from this programme
Part 1
SGLT2 Inhibition in Changing the HF Paradigm
Part 2
Latest Evidence for SGLT2 in HF – 2020 So Far
Part 3
Latest Evidence and Key Upcoming HFrEF Data 2020
Part 4
The Future is Near – Unmet Needs in HFpEF
Faculty Biographies
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.
Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).
Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.
Prof Coats research interests are chronic heart failure, hypertension, and organizational…
Piotr Ponikowski
Head of the Department of Heart Diseases
Piotr Ponikowski is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. His research interests mainly include heart failure (HF), coronary artery disease and cardiac arrhythmias. He has been involved in numerous research projects, such as the benefits of physical rehabilitation in patients with chronic HF, assessment of metabolic derangements in HF (with special interest in iron deficiency), evaluation of reflex control in the cardiorespiratory system in order to optimize assessment and management of patients with HF. He has been involved in numerous clinical trials as main investigator, member of international steering committees, endpoint committees and advisory boards.
Professor Ponikowski is a past-President of the Heart Failure Association of the European Society of Cardiology (ESC) and was a member of the ESC Board. He has been involved in…
Stefan Anker
Professor of Cardiology
Dr Stefan D Anker, Professor of Cardiology and Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany, and served as the 2012–14 President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).